Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Upadacitinib plus topical corticosteroids in atopic dermatitis: Week 52 AD Up study results
Jonathan I. Silverberg, Marjolein de Bruin‐Weller, Thomas Bieber, et al.
Journal of Allergy and Clinical Immunology (2021) Vol. 149, Iss. 3, pp. 977-987.e14
Open Access | Times Cited: 92

Showing 1-25 of 92 citing articles:

European guideline (EuroGuiDerm) on atopic eczema: part I – systemic therapy
Andreas Wollenberg, Maria Kinberger, B.W.M. Arents, et al.
Journal of the European Academy of Dermatology and Venereology (2022) Vol. 36, Iss. 9, pp. 1409-1431
Open Access | Times Cited: 239
JAK inhibitors in the treatment of atopic dermatitis
Raj Chovatiya, Amy S. Paller
Journal of Allergy and Clinical Immunology (2021) Vol. 148, Iss. 4, pp. 927-940
Open Access | Times Cited: 225
Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer
Xue Chen, Qinfan Yao, Xinyu Gu, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 190
Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis
Eric L. Simpson, Kim Papp, Andrew Blauvelt, et al.
JAMA Dermatology (2022) Vol. 158, Iss. 4, pp. 404-404
Open Access | Times Cited: 135
JAK–STAT signaling pathway in the pathogenesis of atopic dermatitis: An updated review
I‐Hsin Huang, Yi‐Teng Hung, Po‐Chien Wu, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 132
Novel insights into atopic dermatitis
Charles F. Schuler, Allison C. Billi, Emanual Maverakis, et al.
Journal of Allergy and Clinical Immunology (2022) Vol. 151, Iss. 5, pp. 1145-1154
Open Access | Times Cited: 107
An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study
Emma Guttman‐Yassky, Eric L. Simpson, Kristian Reich, et al.
The Lancet (2022) Vol. 401, Iss. 10372, pp. 204-214
Closed Access | Times Cited: 91
Systemic treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trials
Alexandro Chu, Melanie Wong, Daniel Rayner, et al.
Journal of Allergy and Clinical Immunology (2023) Vol. 152, Iss. 6, pp. 1470-1492
Open Access | Times Cited: 54
Expert consensus on the systemic treatment of atopic dermatitis in special populations
David N. Adam, Melinda Gooderham, Jennifer Beecker, et al.
Journal of the European Academy of Dermatology and Venereology (2023) Vol. 37, Iss. 6, pp. 1135-1148
Open Access | Times Cited: 47
Treatment of atopic dermatitis: Recently approved drugs and advanced clinical development programs
Svenja Müller, Laura Maintz, Thomas Bieber
Allergy (2024) Vol. 79, Iss. 6, pp. 1501-1515
Open Access | Times Cited: 44
JAK-STAT pathway inhibitors in dermatology
Hélio Amante Miot, Paulo Ricardo Criado, Caio César Silva de Castro, et al.
Anais Brasileiros de Dermatologia (2023) Vol. 98, Iss. 5, pp. 656-677
Open Access | Times Cited: 42
Signaling pathways in macrophages: molecular mechanisms and therapeutic targets
Ming Li, Mengjie Wang, Yuanjia Wen, et al.
MedComm (2023) Vol. 4, Iss. 5
Open Access | Times Cited: 42
The JAK/STAT Pathway and Its Selective Inhibition in the Treatment of Atopic Dermatitis: A Systematic Review
Aikaterini Tsiogka, Maria Kyriazopoulou, George Kontochristopoulos, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 15, pp. 4431-4431
Open Access | Times Cited: 52
Association of Risk of Incident Venous Thromboembolism With Atopic Dermatitis and Treatment With Janus Kinase Inhibitors
Tai‐Li Chen, Ling-Ling Lee, Huei‐Kai Huang, et al.
JAMA Dermatology (2022) Vol. 158, Iss. 11, pp. 1254-1254
Open Access | Times Cited: 41
Oral Janus kinase inhibitors for atopic dermatitis
Daniela Mikhaylov, Benjamin Ungar, Yael Renert‐Yuval, et al.
Annals of Allergy Asthma & Immunology (2023) Vol. 130, Iss. 5, pp. 577-592
Open Access | Times Cited: 35
Atopic Dermatitis Yardstick update
Mark Boguniewicz, Luz Fonacier, Emma Guttman‐Yassky, et al.
Annals of Allergy Asthma & Immunology (2023) Vol. 130, Iss. 6, pp. 811-820
Closed Access | Times Cited: 23
Long-term effectiveness and safety of upadacitinib for Japanese patients with moderate-to-severe atopic dermatitis: a real-world clinical study
Teppei Hagino, Hidehisa Saeki, Eita Fujimoto, et al.
Journal of Dermatological Treatment (2024) Vol. 35, Iss. 1
Open Access | Times Cited: 14
Unraveling Atopic Dermatitis: Insights into Pathophysiology, Therapeutic Advances, and Future Perspectives
Ashutosh Pareek, Lipika Kumari, Aaushi Pareek, et al.
Cells (2024) Vol. 13, Iss. 5, pp. 425-425
Open Access | Times Cited: 12
JAK in the [Black] Box: A Dermatology Perspective on Systemic JAK Inhibitor Safety
Sarina B. Elmariah, Jeffrey S. Smith, Joseph F. Merola
American Journal of Clinical Dermatology (2022) Vol. 23, Iss. 4, pp. 427-431
Closed Access | Times Cited: 37
Tralokinumab Plus Topical Corticosteroids as Needed Provides Progressive and Sustained Efficacy in Adults with Moderate-to-Severe Atopic Dermatitis Over a 32-Week Period: An ECZTRA 3 Post Hoc Analysis
Jonathan I. Silverberg, David N. Adam, Matthew Zirwas, et al.
American Journal of Clinical Dermatology (2022) Vol. 23, Iss. 4, pp. 547-559
Open Access | Times Cited: 35
Effectiveness and Safety of Upadacitinib in the Treatment of Moderate-Severe Atopic Dermatitis: A Multicentric, Prospective, Real-World, Cohort Study
Andrea Chiricozzi, Niccolò Gori, Alessandra Narcisi, et al.
Drugs in R&D (2022) Vol. 22, Iss. 3, pp. 245-252
Open Access | Times Cited: 33
IL‐13, periostin and dipeptidyl‐peptidase‐4 reveal endotype‐phenotype associations in atopic dermatitis
Laura Maintz, Thomas Welchowski, Nadine Herrmann, et al.
Allergy (2023) Vol. 78, Iss. 6, pp. 1554-1569
Open Access | Times Cited: 18
The Use of JAK/STAT Inhibitors in Chronic Inflammatory Disorders
Giuseppina Caiazzo, Anna Caiazzo, Maddalena Napolitano, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 8, pp. 2865-2865
Open Access | Times Cited: 18
Major adverse cardiovascular events in patients with atopic dermatitis treated with oral Janus kinase inhibitors: a systematic review and meta-analysis
C. Ertus, Lucie‐Marie Scailteux, Alain Lescoat, et al.
British Journal of Dermatology (2023) Vol. 189, Iss. 4, pp. 368-380
Closed Access | Times Cited: 18
Janus Kinase Inhibitors for the Treatment of Atopic Dermatitis: Focus on Abrocitinib, Baricitinib, and Upadacitinib
Miguel Nogueira, Tiago Torres
Dermatology Practical & Conceptual (2021), pp. e2021145-e2021145
Open Access | Times Cited: 34
Page 1 - Next Page

Scroll to top